Achieving Mucosal Healing in Inflammatory Bowel Diseases: Which Drug Concentrations Need to Be Targeted?
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Achieving Mucosal Healing in Inflammatory Bowel Diseases: Which Drug Concentrations Need to Be Targeted?
Authors
Keywords
-
Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 106, Issue 5, Pages 945-954
Publisher
Wiley
Online
2019-08-17
DOI
10.1002/cpt.1609
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Optimising infliximab induction dosing for patients with ulcerative colitis
- (2019) Erwin Dreesen et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Comparison of immunoassays for measuring serum levels of golimumab and antibodies against golimumab in ulcerative colitis
- (2019) Anne-Emmanuelle Berger et al. THERAPEUTIC DRUG MONITORING
- Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn’s Disease: A Prospective Multicentre Study
- (2019) Niels Vande Casteele et al. Journal of Crohns & Colitis
- P589 A population pharmacokinetic model to improve mucosal healing upon golimumab induction therapy in patients with ulcerative colitis
- (2019) W Kantasiripitak et al. Journal of Crohns & Colitis
- Ustekinumab Exposure-outcome Analysis in Crohn’s Disease Only in Part Explains Limited Endoscopic Remission Rates
- (2019) Bram Verstockt et al. Journal of Crohns & Colitis
- Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases
- (2019) Andres J. Yarur et al. DIGESTIVE DISEASES AND SCIENCES
- Early vedolizumab trough levels at induction in inflammatory bowel disease patients with treatment failure during maintenance
- (2019) Claire Liefferinckx et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Defining a minimal effective serum trough concentration of secukinumab in psoriasis: a step towards personalized therapy
- (2019) Rani Soenen et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study
- (2018) W. Yacoub et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease
- (2018) A. Barré et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases
- (2018) Erwin Dreesen et al. Clinical Gastroenterology and Hepatology
- Loss of Response to Vedolizumab and Ability of Dose Intensification to Restore Response in Patients With Crohn’s Disease or Ulcerative Colitis: a Systematic Review and Meta-analysis
- (2018) Laurent Peyrin-Biroulet et al. Clinical Gastroenterology and Hepatology
- Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease
- (2018) Luc J. J. Derijks et al. CLINICAL PHARMACOKINETICS
- Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease
- (2018) Omoniyi J. Adedokun et al. GASTROENTEROLOGY
- P649 Comparison of the KU Leuven ustekinumab concentration assay and the antibodies-to-ustekinumab assay with assays developed at Janssen R&D and used in clinical studies of IBD patients
- (2018) J C Marini et al. Journal of Crohns & Colitis
- Vedolizumab Drug Level Correlation With Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease
- (2018) Badr Al-Bawardy et al. INFLAMMATORY BOWEL DISEASES
- OUP accepted manuscript
- (2018) Journal of Crohns & Colitis
- Golimumab Dried Blood Spot Analysis (GOUDA): a Prospective Trial Showing Excellent Correlation with Venepuncture Samples and More Detailed Pharmacokinetic Information
- (2018) Iris Detrez et al. AAPS Journal
- Exposure–efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn’s Disease
- (2017) Maria Rosario et al. Journal of Crohns & Colitis
- Immunoassays for Measuring Serum Concentrations of Monoclonal Antibodies and Anti-biopharmaceutical Antibodies in Patients
- (2017) François Darrouzain et al. THERAPEUTIC DRUG MONITORING
- Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Inflammatory Bowel Disease
- (2017) Iris Detrez et al. THERAPEUTIC DRUG MONITORING
- Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases
- (2016) Bella Ungar et al. Clinical Gastroenterology and Hepatology
- Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis
- (2016) Johannan F. Brandse et al. Clinical Gastroenterology and Hepatology
- Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis
- (2016) Konstantinos Papamichael et al. Clinical Gastroenterology and Hepatology
- Endoscopic Mucosal Healing Predicts Favorable Clinical Outcomes in Inflammatory Bowel Disease
- (2016) Andrew R. Reinink et al. INFLAMMATORY BOWEL DISEASES
- Higher Adalimumab Levels Are Associated with Histologic and Endoscopic Remission in Patients with Crohnʼs Disease and Ulcerative Colitis
- (2016) Andres J. Yarur et al. INFLAMMATORY BOWEL DISEASES
- Variability in Golimumab Exposure: A ‘Real-Life’ Observational Study in Active Ulcerative Colitis
- (2016) Iris Detrez et al. Journal of Crohns & Colitis
- Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies
- (2016) Omoniyi J. Adedokun et al. Journal of Crohns & Colitis
- Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis
- (2016) Konstantinos Papamichael et al. Journal of Crohns & Colitis
- Higher Adalimumab Drug Levels are Associated with Mucosal Healing in Patients with Crohn’s Disease
- (2016) E. Zittan et al. Journal of Crohns & Colitis
- Generation and characterization of a unique panel of anti-adalimumab specific antibodies and their application in therapeutic drug monitoring assays
- (2016) Sumin Bian et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- Rapid Test for Infliximab Drug Concentration Allows Immediate Dose Adaptation
- (2016) Thomas Van Stappen et al. Clinical and Translational Gastroenterology
- Loss of Response to Anti-TNFs: Definition, Epidemiology and Management
- (2016) Giulia Roda et al. Clinical and Translational Gastroenterology
- Comparison study of two commercially available methods for the determination of golimumab and anti-golimumab antibody levels in patients with rheumatic diseases
- (2015) Sergio Martín et al. CLINICAL CHEMISTRY AND LABORATORY MEDICINE
- The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study
- (2015) Andres J Yarur et al. GUT
- Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: Adding value to current practice
- (2015) Niels Vande Casteele et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis
- (2014) Omoniyi J. Adedokun et al. GASTROENTEROLOGY
- Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disease
- (2014) Iris Dotan et al. INFLAMMATORY BOWEL DISEASES
- Tailoring anti-TNF therapy in IBD: drug levels and disease activity
- (2014) Shomron Ben-Horin et al. Nature Reviews Gastroenterology & Hepatology
- Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease
- (2013) Jean–Frédéric Colombel et al. Clinical Gastroenterology and Hepatology
- Association Between Pharmacokinetics of Adalimumab and Mucosal Healing in Patients With Inflammatory Bowel Diseases
- (2013) Xavier Roblin et al. Clinical Gastroenterology and Hepatology
- Definition and evaluation of mucosal healing in clinical practice
- (2013) Silvia Mazzuoli et al. DIGESTIVE AND LIVER DISEASE
- Targeting TNF-α for the treatment of inflammatory bowel disease
- (2013) Thomas Billiet et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays
- (2012) N. Vande Casteele et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Immunogenicity and autoimmunity during anti-TNF therapy
- (2012) F. Atzeni et al. AUTOIMMUNITY REVIEWS
- Mucosal healing in inflammatory bowel diseases: a systematic review
- (2012) Markus F Neurath et al. GUT
- Review article: loss of response to anti-TNF treatments in Crohn’s disease
- (2011) S. Ben-Horin et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Epidemiology and Natural History of Inflammatory Bowel Diseases
- (2011) Jacques Cosnes et al. GASTROENTEROLOGY
- Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis
- (2009) C H Seow et al. GUT
- Clinical implications of mucosal healing for the management of IBD
- (2009) Guillaume Pineton de Chambrun et al. Nature Reviews Gastroenterology & Hepatology
- Withdrawal of Immunosuppression in Crohn's Disease Treated With Scheduled Infliximab Maintenance: A Randomized Trial
- (2008) Gert Van Assche et al. GASTROENTEROLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started